References
- The Italian cooperative study group on chronic myeloid leukemia (1992). A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients, Haematologica, 77, 204–214.
- Allan, N. C., Richards, S. M., Shepherd, P.C. A. and on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia (1995). UK medical research council randomised, multicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response, Lancet, 345, 1392–1397.
- Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S., Tsubaki, K., Miura, Y., Omine, M., Kobayashi, T., Naoe, T., Ohshima, T., Hirashima, K., Ohtake, S., Takahashi, I., Morishima, Y., Naito, K., Asou, N., Tanimoto, M., Sakuma, A., Yamada, K. and the Kouseisho Leukemia Study Group (1995). A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase, Blood, 86, 906–916.
- Kantarjian, H. M., Smith, T. L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M. and the Leukemia Service (1995). Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy, Ann Intern Med, 122, 254–261.
- Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H. J., Paralle, H., Hossfeld, D. K., Queiβer, W., Löffler, H., Hochhaus, A., Heinze, B., Georgii, A., Bartram, C. R., Grieβhammer, M., Bergmann, L., Essers, U., Falge, C., Queiβer, U., Meyer, P., Scmitz, N., Eimermacher, H., Walther, F., Fett, W., Kleeberg, U. R., Käbisch, A., Nerl, C., Zimmermann, R., Meuret, G., Tichelli, A., Kanz, L., Tigges, F.-J., Schmid, L., Brockhaus, W., Tobler, A., Reiter, A., Perker, M., Emmerich, B., Verpoort, K., Zankovich, R., Wussow, P. V., Prümmer, O., Thiele, J., Buhr, T., Carbonell, F., Ansari, H. and the German CML Study Group (1994). Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia, Blood, 84, 4064–4077.
- Speck, B., Bortin, M. M., Champlin, R., Goldman, J. M., Herzig, R. H., McGlave, P. B., Messner, H. A., Weiner, R. S. and Rimm, A. A. (1984). Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia, Lancet, 665–668.
- Talpaz, M., Kantarjian, H. M., McCredie, K. B., Kea ting, M. J., Trujillo, J. and Gutterman, J. (1987). Clinical investigation of human alpha interferon in chronic myelogenous leukemia, Blood, 69, 1280–1288.
- Cortes, J., Kantarjian, H., O'Brien, S., Robertson, L. E., Pierce, S. and Talpaz, M. (1996). Results of interferon-α therapy in patients with chronic myelogenous leukemia 60 years of age and older, Am J Med, 100, 452–455.
- Ozer, H., George, S. L., Schiffer, C. A., Rao, K., Rao, P. N., Wurster-Hill, D. H., Arthur, D. D., Powell, B., Gottlieb, A., Peterson, B. A., Rai, K., Testa, J. R., LeBeau, M., Tantravahi, R. and Bloomfield, C.D. (1993). Prolonged subcutaneous administration of recombinant α 2b interferon in patients with previously untreated Philadelphia chromosome-positive chromephase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583, Blood, 82, 2975–2984.
- Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.-F. and Tanzer, J., for the French Chronic Myeloid Leukemia Study Group (1997). Interferon-α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia, N Engl J Med, 337, 223–229.